Big Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies

Big Picture Bio identifies, designs and optimises cancer combination therapies using a generative world model of how tumours, immune cells and surrounding tissue interact across disease sites and patient subgroups. Pairing that modelling with targeted wet-lab validation, the platform selects drug combinations and sequencing intended to minimise residual disease in cancer and immune-mediated diseases.